philip philip, md on the reliability of msi-high as a predictor of response to opdivo in mcrc
Published 8 years ago • 54 plays • Length 1:37
Download video MP4
Download video MP3
Similar videos
-
3:24
howard hochster, md on the reliability of msi-high as a predictor of response to nivolumab
-
0:53
philip philip, md on the importance of ipilimumab prior to nivolumab in mcrc patients
-
0:58
jeffrey a. meyerhardt, md on the reliability of msi-high as a predictor of response in mcrc
-
1:30
tanios bekaii-saab, md on msi-high as an mcrc response predictor to nivolumab (opdivo)
-
2:04
philip philip, md, shares opinion on treatment of a brca pancreatic cancer patient
-
2:43
philip philip, md, phd, frcp, considers the impact of immunotherapy agents in pancreatic cancer
-
2:21
philip philip, md, on what we’ve learned about the duration of therapy in the adjuvant crc setting
-
2:00
dr. overman on nivolumab and ipilimumab in patients with msi-h crc
-
1:59
philip philip, md, considers the benefits of immunotherapy in treating gastrointestinal cancer
-
1:32
philip philip, md, on which molecular tests to order for a newly diagnosed crc patient
-
2:19
philip philip, md, on the outcomes of the polo study and its importance to physicians
-
0:56
philip philip, md on stivarga (regorafenib) dosage in 2nd line treatment of mcrc
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
1:14
philip philip md, phd, frcp, on brca gene mutations & outcomes in pancreatic cancer
-
1:35
philip philip, md, on integrating immunotherapy into existing treatment regimens for crc patients
-
5:17
philip philip md, phd, frcp, discusses outcomes from the polo trial in pancreatic cancer
-
4:42
philip philip md, phd, frcp, on the apact trial in surgically resected pancreatic adenocarcinoma
-
2:51
philip philip, md, phd, frcp, on the implications of the lapact study presented at asco 2018
-
3:20
philip philip md, phd, frcp, on promising novel therapies for pancreatic cancer
Clip.africa.com - Privacy-policy